BioFire Diagnostics provides syndromic infectious disease diagnostics, focusing on rapid and accurate molecular testing.

Kirk Ririe

Carl Wittwer

Randy Rasmussen

BioFire Diagnostics

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System.

The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. Whether you’re trying to determine optimal therapy for a septic patient or pinpoint which respiratory pathogen is making a young child sick, the BioFire System can provide definitive answers—fast.

BioFire Diagnostics, LLC

The BioFire brand is evolving and there are some changes we’re excited to show you. bioMérieux, a global presence and world leader in infectious disease diagnostics, acquired BioFire in 2014 and it’s time to align our two companies. In January 2022, the BioFire product line will be folded into the bioMérieux product portfolio. As a company, it will simply be called bioMérieux. Read our newest blog post to see what the future holds for this amazing company. #WeArebioMerieux #NewBeginnings https://bit.ly/3o01mfV

Metric
Company Name	BioFire Diagnostics	Biocartis Group NV
Symbol		BCART
MSH ID	COM:BIOFIREDX	COM:BIOCARTIS
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Diagnostics	Medical - Diagnostics & Research
Country	US	BE
Stage	Venture Round
Employee Count	781	526
Website	biofiredx.com	biocartis.com
LinkedIn	biofire-diagnostics-inc
Founders

Metric
Market Cap		28.77M
Enterprise Value
Monthly Web Traffic	81.66K
Web Traffic Growth	10.40
Valuation
Raised Capital	45M

Metric
Revenue		60.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit		29.24M
EBITDA		-46.11M
Operating Income		-49.38M
Net Income		-69.06M
EPS		-1.14
Diluted EPS		-1.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.32
Operating Profit Margin		-0.71
EBITDA Margin		-0.76
Net Profit Margin		-1.11
Return on Equity		1.81
Return on Assets		-0.74
Return on Capital Employed		-0.67

COM:BIOFIREDX

BioFire Diagnostics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.27
P/B Ratio		-0.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.36
EV Multiple		2.43

Metric
Days Sales Outstanding		165.75
Days Payables Outstanding		143.89
Days Inventory Outstanding		127.62
Operating Cycle		238.75
Cash Conversion Cycle		189.50
Asset Turnover		0.81

Metric
Operating Cash Flow		-47.38M
Free Cash Flow		-49.42M
Cash Flow to Debt		-0.42
Operating Cash Flow/Sales		-0.82
Free Cash Flow Yield		-1.72

Metric
Cash & Equivalents		26.33M
Accounts Receivable		1.67M
Inventory		19.97M
Goodwill
Debt to Capitalization		1.55
Debt to Assets		1.07
Current Ratio		1.65
Quick Ratio		1.49

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.67
SG&A to Revenue		0.06